title: The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
abstract: BACKGROUND
  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery.
  
  
  METHODS
  The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS).
  
  
  RESULTS
  Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P = 0.427).
  
  
  CONCLUSIONS
  These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Prospective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin.
authors.affiliation: Deaprtment of General Surgery, Hospital Infanta Cristina, Cordoba, Spain.
authors.forename: Arancha
authors.initials: A
authors.lastname: Prada-Villaverde
authors.forename: Jesus
authors.initials: J
authors.lastname: Esquivel
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Lowy
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
authors.forename: Terence
authors.initials: T
authors.lastname: Chua
authors.forename: Joerg
authors.initials: J
authors.lastname: Pelz
authors.forename: Dario
authors.initials: D
authors.lastname: Baratti
authors.forename: Joel M
authors.initials: JM
authors.lastname: Baumgartner
authors.forename: Richard
authors.initials: R
authors.lastname: Berri
authors.forename: Pedro
authors.initials: P
authors.lastname: Bretcha-Boix
authors.forename: Marcello
authors.initials: M
authors.lastname: Deraco
authors.forename: Guillermo
authors.initials: G
authors.lastname: Flores-Ayala
authors.forename: Olivier
authors.initials: O
authors.lastname: Glehen
authors.forename: Alberto
authors.initials: A
authors.lastname: Gomez-Portilla
authors.forename: Santiago
authors.initials: S
authors.lastname: González-Moreno
authors.forename: Martin
authors.initials: M
authors.lastname: Goodman
authors.forename: Evgenia
authors.initials: E
authors.lastname: Halkia
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kusamura
authors.forename: Mecker
authors.initials: M
authors.lastname: Moller
authors.forename: Guillaume
authors.initials: G
authors.lastname: Passot
authors.forename: Marc
authors.initials: M
authors.lastname: Pocard
authors.forename: George
authors.initials: G
authors.lastname: Salti
authors.forename: Armando
authors.initials: A
authors.lastname: Sardi
authors.forename: Maheswari
authors.initials: M
authors.lastname: Senthil
authors.forename: John
authors.initials: J
authors.lastname: Spiliotis
authors.forename: Juan
authors.initials: J
authors.lastname: Torres-Melero
authors.forename: Kiran
authors.initials: K
authors.lastname: Turaga
authors.forename: Richard
authors.initials: R
authors.lastname: Trout
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D013505:Digestive System Surgical Procedures; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D016685:Mitomycin
keywords: colorectal cancer with peritoneal carcinomatosis; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy (HIPEC)